According to the RNC Pharma® database “Audit of Retail Sales of Medicinal Products in Russia (total sell-out)”, in Q1–Q3 2025, Russians spent RUB 35.1 billion (in retail prices, including VAT) on throat treatment medicines (EphMRA group R02), purchasing a total of 83.5 million packages. Compared with the same period in 2024, value sales increased by 12%, while volume sales decreased by 2.1%.

The highest consumption levels in this category were recorded in 2022, when pharmacies sold 128.8 million packages. Since then, unit sales have been declining annually, even as the market’s value continues to grow — a result of rising average prices. For instance, while in 2022 the average price per package did not exceed RUB 309, by the end of the first nine months of 2025 it had reached RUB 420, marking a 14.5% increase year-on-year and nearly 36% growth over three years.

In 2025, the highest monthly spending on this product group was observed in September, when 13.4 million packages were sold for a total of RUB 5.7 billion. Interestingly, the sales peak in 2024 also occurred in early autumn, with 13.8 million packages sold for RUB 5.1 billion.

As of Q1–Q3 2025, the retail market included 85 brands from 88 companies. Over the past few years, seven new brands have been added to the category, most of them of Russian origin. The dominant product form remains lozenges and tablets for oral dissolution, accounting for over 60% of both value and volume sales.

The leading brand in the category was Grammidin (Valenta, Russia), with consumer spending exceeding RUB 6 billion and a 17.2% market share. Compared with January–September 2024, its sales increased by 14.6% in value and 0.6% in volume. Strepsils (Reckitt Benckiser) ranked second, showing +15% value growth but a –9.6% decline in volume, with a 12% share in market value. In third place was Tantum (Angelini), accounting for 8.1% of total sales and demonstrating impressive growth of +25.5% in value and +10.7% in volume. Notably, Angidak (Groteks, Russia), a direct analogue of Tantum, ranked fourth, but showed only +1% value growth year-on-year.

Among the top 10 brands, only two recorded a decline in value sales versus Q1–Q3 2024: Septolete (KRKA, –3%) and Ingalipt (produced by 12 different manufacturers, –2%). The strongest growth was seen for the homeopathic product Lymphomyosot (Heel, Germany), with +52.9% in value and +40.5% in volume, followed by Dorithricin (Medice Pharma, Germany), up +40.1% in value and +17.4% in volume.

Top 10 Throat Treatment Medicine Brands (EphMRA Group R02) by retail sales value in the Russian pharmaceutical market, Q1–Q3 2025